Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma

Three reports address the protection of the vulnerable population of patients with hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest that some patients who fail to mount a B-cell response to vaccine may nevertheless have protective T cell responses. As a group,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2022-01, Vol.139 (1), p.137-142
Hauptverfasser:	Enßle, Julius C., Campe, Julia, Schwenger, Amelie, Wiercinska, Eliza, Hellstern, Helen, Dürrwald, Ralf, Rieger, Michael A., Wolf, Sebastian, Ballo, Olivier, Steffen, Björn, Serve, Hubert, Bonig, Halvard, Rabenau, Holger F., Widera, Marek, Ciesek, Sandra, Metzler, Ivana von, Ullrich, Evelyn
Format:	Artikel
Sprache:	eng
Schlagworte:	BNT162 Vaccine - pharmacology BNT162 Vaccine - therapeutic use COVID-19 - immunology COVID-19 - prevention & control Humans Immunity, Cellular Letters to Blood Multiple Myeloma - complications Multiple Myeloma - immunology SARS-CoV-2 - immunology T-Lymphocytes - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!